Post by
piduks on Jun 15, 2024 11:41am
Global distribution includes China and rest of world.
This is something Medipharm Labs does not have irregardless of their existing business alliances. SK Capital Partners could enhance their monetization of privately held Apotex by way of listing part of the company publicly while retaining control through a reverse IPO via Medipharm Labs and no different than the reverse IPO Medipharm Labs executed to become a public company. The goal and only goal is to generate capital gains. Global commercialization requires high capacity production facilities and not the 'mom and pop shop' capacity existing currenlty within Medipharm Labs.
Elmer Fudd has thus shown an incapability of taking the company to the next level while waisting good oxygen talking about M&A activities within cannabis companies that are on the brink of going belly up and unpaid excise taxes.
Monetize Apotex through the capital markets by way of Medipharm Labs and 5 new drugs in the very near term, 2 of Brazil and 3 of the U.S.